BSX · Intrinsic value
Is Boston Scientific Corporation (BSX) overvalued or undervalued?
Boston Scientific Corporation (BSX) trades at the delayed market price of $44.39 a share. That price already implies revenue growth of 7.6% a year for 5 years. TickerWorth's fair value is $45.23 a share (priced within our range of $27.74 – $59.72). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is BSX fairly valued?
- Fair value
- $45.23
- Market price
- $44.39
- Upside to fair value
- +1.9%
- Verdict
- Priced within our range of $27.74 – $59.72
Reverse DCF: Today's price implies revenue growth of 7.6% a year for 5 years; our model assumes 6.5% a year on average over the same horizon.
What is BSX's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: recent price trend has been weak.
- Value · 70 of 100
Cheaper than 70% of Healthcare companies in US
- Price vs worth · 52 of 100
- Quality · 71 of 100
More profitable than 71% of Healthcare companies in US
- Financial health · 31 of 100
Financially stronger than 31% of Healthcare companies in US
- Growth · 44 of 100
Growing faster than 44% of Healthcare companies in US
- Momentum · 3 of 100
Outperformed 3% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
BSX DCF valuation, input by input
At a recent price of $44.39, Boston Scientific Corporation (BSX) trades roughly at TickerWorth's blended fair value of $45.23 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices BSX in line with our estimate of what the business is intrinsically worth. Our fair value sits above the market, an implied +1.9% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values BSX at about $41.74 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Boston Scientific Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 7.5%, with a long-run terminal growth rate of 2.5%. About 79% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 7.6% annual revenue growth for BSX. Our base case instead compounds to about 6.5% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, BSX's modeled DCF value ranges from about $28.40 to $81.34 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Boston Scientific Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of BSX's intrinsic value. Figures update as new filings and prices come in.
Every input behind BSX's DCF
| Input | Value |
|---|---|
| Base-year revenueBOSTON SCIENTIFIC CORPORATION FY2025 10-K (accession 0000885725-26-000010): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $20,074,000,000 |
| Base EBIT marginBOSTON SCIENTIFIC CORPORATION FY2025 10-K (accession 0000885725-26-000010): us-gaap:OperatingIncomeLoss 3,613,000,000 / revenue 20,074,000,000 = 18.00%, FY2025. | 18.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 9% → 8% → 7% → 5% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.57 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesBOSTON SCIENTIFIC CORPORATION FY2025 10-K (accession 0000885725-26-000010): WeightedAverageNumberOfDilutedSharesOutstanding = 1,494,500,000 shares, FY2025. | 1,494M |
| Market priceDelayed quote · as of 2026-10-19 13:54 UTC | $44.39 |
Change BSX's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Boston Scientific Corporation do?
What does it do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 59,000 people.
How does it make money?
The business turns $21.0B in annual revenue into profit. Out of every $100 of sales, about $23 is left as operating profit (operating margin of 22.9%), after a 69% gross margin on the products/services it sells. After all costs, taxes and interest, 17.5% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.5× equity), can just cover its short-term bills (1.2× current ratio), and is currently profitable.
Who at BSX filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| O'Connor Padraig Andrew | EVP, Global Operations | Option exercise | — | Form 4 for O'Connor Padraig Andrew (opens sec.gov in a new tab) | |
| O'Connor Padraig Andrew | EVP, Global Operations | Shares withheld (tax) | $27,425.79 | Form 4 for O'Connor Padraig Andrew (opens sec.gov in a new tab) | |
| Morano Susan E | Director | Open-market buy | $100,407.78 | Form 4 for Morano Susan E (opens sec.gov in a new tab) | |
| Woodworth Emily | SVP, Global Controller and CAO | Code I | $149,986.70 | Form 4 for Woodworth Emily (opens sec.gov in a new tab) | |
| Monson Jonathan | EVP and CFO | Code I | $499,957.68 | Form 4 for Monson Jonathan (opens sec.gov in a new tab) | |
| Habiger David C | Director | Open-market buy | $99,936.90 | Form 4 for Habiger David C (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is BSX's intrinsic value?
TickerWorth's blended fair value for Boston Scientific Corporation (BSX) is $45.23 per share, versus a market price of $44.39 (roughly at fair value).
Is BSX overvalued or undervalued?
On our blended fair value BSX looks in line with fair value at $44.39. This is an educational estimate, not advice.
What discount rate is used for BSX?
A WACC of 7.5% and a terminal growth rate of 2.5%.
Is Boston Scientific stock undervalued?
TickerWorth's fair value for Boston Scientific Corporation (BSX) is $45.23 against a market price of $44.39. Our read: Priced within our range of $27.74 – $59.72. This is a model estimate, not investment advice.
Boston Scientific (BSX) DCF valuation and fair value
Our fair value for Boston Scientific Corporation (BSX) is $45.23, built on a 7.5% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Boston Scientific stock?
Today's price implies revenue growth of 7.6% a year for 5 years; our model assumes 6.5% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $44.39. A model estimate, not investment advice.
Boston Scientific (BSX) insider trading
The most recent insider filing (SEC Form 4) for Boston Scientific Corporation (BSX): O'Connor Padraig Andrew, EVP, Global Operations, option exercise on 2026-09-02. The latest filings are listed on this page. A disclosure, not a signal to trade.
How does BSX compare with its peers?
People who read BSX also read
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.